Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis

被引:19
作者
Martinez, FJ [1 ]
Anzueto, A [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA
关键词
acute exacerbations of chronic bronchitis; antibiotics; chronic obstructive pulmonary disease; fluoroquinolones; resistance; short-course therapy;
D O I
10.1016/j.amjmed.2005.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute exacerbations of chronic bronchitis (AECB), which are characteristic of chronic obstructive pulmonary disease (COPD), contribute to morbidity and decreased quality of life for patients with COPD. A significant proportion of these exacerbations are due to bacterial infections. The Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria provide guidance for choosing the optimal drug at its optimal dose and duration for antimicrobial treatment of AECB due to bacterial infection. Evidence-based guidelines recommend stratifying patients according to risk factors to improve selection of targeted, antimicrobial therapy. With increasing rates of resistance to some antimicrobials, resistance is also an important consideration for reducing treatment failures and decreasing the need for further pharmacologic treatment. Fluoroquinolones are recommended as first-line therapy for patients with chronic bronchitis who have risk factors; gatifloxacin, gemifloxacin, and levofloxacin are highly active against commonly encountered pathogens. Safety profiles are an important consideration because adverse events and poor tolerability can reduce patient adherence rates, which in turn can lead to poorer outcomes. Safety profiles also become an important consideration as shorter-course, higher-dose therapies become more prevalent. First-line therapy with a well-tolerated antibiotic that is active against the predominant pathogens, combined with low resistance rates and a convenient once-a-day dosing regimen, may reduce overall costs. Fluoroquinolones exhibit low resistance, good activity levels, and high respiratory penetration, and they are particularly well suited for shorter-course, higher-dose regimens in selected patients. Shorter-course, higher dose regimens, in turn, may be more effective, cost-efficient, and appropriate for controlling the rise of resistance than standard regimens. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 42 条
[21]   Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae [J].
Lister, PD .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (01) :43-49
[22]   Pharmaco dynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model:: Impact of area under the curve/MIC ratios on eradication [J].
Lister, PD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :69-74
[23]   Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval [J].
Lode, H ;
Eller, J ;
Linnhoff, A ;
Ioanas, M .
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (06) :947-953
[24]   Update to the Latin American Thoracic Association (ALAT) recommendations on infectious exacerbation of chronic obstructive pulmonary disease [J].
Luna, JM ;
Jardim, JR ;
López, H ;
Luna, CM ;
Mazzei, JA ;
Stamboulian, D ;
de Oliveira, JCA ;
Pereira, J ;
Díaz, A ;
Lisboa, C ;
Saldías, F ;
Maldonado, D ;
Torres, L ;
Selmo, SM ;
Miravitlles, M ;
de Castro, FR ;
Torres, A ;
Anzueto, A ;
Ramírez, J ;
Díaz, A ;
Padilla, RP ;
Ramírez, A ;
Sansores, R ;
Carrasco, I ;
Matsuno, A .
ARCHIVOS DE BRONCONEUMOLOGIA, 2004, 40 (07) :315-325
[25]  
MARTINEZ FJ, 2004, J CLIN OUTCOMES MANA, V11, P659
[26]   Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD [J].
Miravitlles, M ;
Murio, C ;
Guerrero, T ;
Gisbert, R .
CHEST, 2002, 121 (05) :1449-1455
[27]   Quinolone-resistant Haemophilus influenzae in a long-term care facility:: Clinical and molecular epidemiology [J].
Nazir, J ;
Urban, C ;
Mariano, N ;
Burns, J ;
Tommasulo, B ;
Rosenberg, C ;
Segal-Maurer, S ;
Rahal, JJ .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (11) :1564-1569
[28]   Treatment cost of acute exacerbations of chronic bronchitis [J].
Niederman, MS ;
McCombs, JS ;
Unger, AN ;
Kumar, A ;
Popovian, R .
CLINICAL THERAPEUTICS, 1999, 21 (03) :576-591
[29]  
*ORTH MCNEIL PHARM, 2003, P TRUST 7 2002 2003
[30]   Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis [J].
Pechère, JC ;
Lacey, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 :19-24